Market Data
Market Cap₹300.71 Cr.
52W High₹49.98
Current Price₹39.24
52W Low₹23.12
Down from 52W High21.5 %
Face Value₹10
Performance
ROCE9.19 %
ROE8.56 %
EPS (TTM)₹0.52
EPS Prev Qtr₹0.85
EPS Last Year₹-0.07
EBITDA Qtr₹3.2 Cr.
Book Value₹21
Financial Health
Debt/Equity0.33
Debt/Profit3.81
Total Assets₹281.129 Cr.
Promoter Holding31.36 %
Earning Power3.71 %
Valuation
Stock P/E23.08
Industry P/E33.3
Price to Book1.9
Price to Sales1.46
Graham Number₹28.11
Key Metrics
__derived
1
Face Value
₹10
About Ambalal Sarabhai Enterprises Ltd
Healthcare · Pharmaceuticals
Ambalal Sarabhai Enterprises Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹300.71 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 8.0% YoY, Profit fell 51.6% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 40.34 | 44.45 | 52 | 65.49 | 43.56 |
| ↳ QoQ Growth | - | +10.2% | +17.0% | +25.9% | -33.5% |
| Expenses | 39.73 | 45 | 48.88 | 60.84 | 40.37 |
| Operating Profit | 0.6 | -0.55 | 3.12 | 4.65 | 3.2 |
| OPM % | 1.49% | -1.24% | 6% | 7.1% | 7.35% |
| Other Income | 8.36 | 1.62 | 2.58 | 2.61 | 2.03 |
| Interest | 1.01 | 0.96 | 0.7 | 1.42 | 0.98 |
| Depreciation | 0.88 | 1.06 | 0.96 | 1.05 | 1.35 |
| EBITDA | 1.48 | 0.51 | 4.08 | 5.7 | 4.55 |
| EBITDA Margin % | 3.67% | 1.15% | 7.85% | 8.7% | 10.45% |
| Profit Before Tax | 7.93 | -0.04 | 4.36 | 6.25 | 4.68 |
| Tax % | -3.66% | -1,300% | 16.51% | -4% | 14.96% |
| Net Profit | 8.22 | -0.56 | 3.64 | 6.5 | 3.98 |
| ↳ QoQ Growth | - | -106.8% | +750.0% | +78.6% | -38.8% |
| EPS | 1.07 | -0.07 | 0.4 | 0.85 | 0.52 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 202.28 | 205.5 |
| Expenses | 194.45 | 195.09 |
| Operating Profit | 7.82 | 10.42 |
| OPM % | 3.87% | 5.07% |
| Other Income | 15.17 | 8.84 |
| Interest | 4.09 | 4.06 |
| Depreciation | 3.95 | 4.42 |
| Profit Before Tax | 18.5 | 15.25 |
| Tax % | 3.78% | 11.08% |
| Net Profit | 17.8 | 13.56 |
| EPS | 2.25 | 1.7 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
17.77%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
8.56%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 76.63 | 76.6333 |
| Reserves | 63.34 | 81.7244 |
| Borrowings | 50.88 | 51.65 |
| Other Liabilities | 79.19 | 71.12 |
| Total Liabilities | 270.04 | 281.1287 |
| Fixed Assets | 62.98 | 90.699 |
| CWIP | 0.01 | 1.8321 |
| Investments | 31.93 | 32.1 |
| Other Assets | 175.12 | 156.5 |
| Total Assets | 270.04 | 281.1287 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 13.4 |
| Cash from Investing Activity | -10.2546 |
| Cash from Financing Activity | -1.8496 |
| Net Cash Flow | 1.2958 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 414.08 |
| ROCE % | 3.41% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 31.35% | 31.36% | 31.36% | 31.36% |
| FIIs % | 0.34% | 0.34% | 0% | 0% |
| DIIs % | 0.01% | 0.01% | 0.01% | 0.01% |
| Public % | 58.36% | 58.45% | 58.67% | 58.9% |
| No. of Shareholders | 1,70,015 | 1,68,396 | 1,67,599 | 1,67,066 |
Major Shareholders (>1%)
- Sarabhai Holdings Private LimitedPromoter and Promoter Group25.77%
- Haryana Containers LimitedPublic Shareholding2.28%
- Sharad Kanayalal ShahPublic Shareholding1.46%
As of 2026-06-30View all shareholders →